WE DESIGN BREAKTHROUGH MEDICINES AT NIMBUS

The heart of our approach is using collaboration to assemble a powerful structure-based drug discovery engine. Our ‘special sauce’ is applying that engine and our unique collective expertise to drive target selection and the design of novel molecules that become breakthrough medicines.

TARGET SELECTION

We identify targets known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. Our targets play causal roles in diseases of immunology, oncology and metabolism; drugging them with efficacious small molecules has the potential to transform patients’ lives.

STRUCTURE-BASED DRUG DISCOVERY ENGINE

We apply leading-edge computational chemistry, in concert with other technologies, to more effectively use protein structure to drug targets and modulate their functional activity.

STRUCTURE-BASED DISCOVERY

ENGINE

STRUCTURAL BIOLOGY

We deploy a range of technologies, including X-ray crystallography and cryo-electron microscopy (cryo-EM) to generate atomic-resolution structural data on our targets — in some cases, for proteins that have never before been successfully mapped.

COMPUTATIONAL CHEMISTRY

We leverage the technology of our founding partner Schrödinger to perform physics-based analyses of our targets’ active and allosteric sites and to design small molecule modulators with the desired binding mode, functional activity and selectivity.

MOLECULAR SCIENCES

Our comprehensive expertise spans protein science, biophysics, enzymology and screening. This assures the optimization of our therapeutic candidates across a stringent set of drug-like properties.

Breakthroughs by design

Our resulting potent and selective small molecule compounds provide the means for us to gain a deeper understanding of biology and develop new therapies for clinical evaluation in patients.

Back to Top

location

130 Prospect Street, Suite 301
Cambridge, MA 02139
USA

call US

857-999-2009